Validating the Portal Population of the United Kingdom Multiple Sclerosis Register
Publication date: Available online 25 May 2018 Source:Multiple Sclerosis and Related Disorders Author(s): RM Middleton, WJ Rodgers, J Chataway, K Schmierer, D Rog, I Galea, A Akbari, K Tuite-Dalton, H Lockhart-Jones, D Griffiths, DG Noble, KH Jones, A Al-Din, M Craner, N Evangelou, P Harman, T Harrower, J Hobart, H Husseyin, M Kasti, C Kipps, G McDonnell, C Owen, O Pearson, W Rashid, H Wilson, DV Ford The UK Multiple Sclerosis Register (UKMSR) is a large cohort study designed to capture ‘real world’ information about living with multiple sclerosis (MS) in the UK from diverse sources. The primary source of data...
Source: Multiple Sclerosis and Related Disorders - May 25, 2018 Category: Neurology Source Type: research

Analysing the Relationship between Polysomnographic Measures of Sleep with Measures of Physical and Cognitive Fatigue in People with Multiple Sclerosis.
Conclusions Sleep impairment is a very common problem in people with MS justifying routine polysomnographic evaluation. We have found evidence that though sleep impairment is not related to physical fatigue, it is strongly related to cognitive fatigue. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 24, 2018 Category: Neurology Source Type: research

A case of Takotsubo syndrome during a multiple sclerosis brainstem relapse
Conclusion Our case adds to previous reports in this field and calls for awareness of this exceptional extra-neurological manifestation of MS. It seems also to confirm the possible association between MS relapses and ovarian stimulation. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 24, 2018 Category: Neurology Source Type: research

Mortality from Listeria monocytogenes Meningoencephalitis following escalation Alemtuzumab Therapy for Relapsing-Remitting Multiple Sclerosis,
We report the case of a patient who died from the rare complication of Listeriosis in the immediate phase following Alemtuzumab administration one month after discontinuing dimethyl fumarate (DMF). There is considerable overlap with typical post-infusion symptoms therefore high surveillance and low threshold for empirical or possible prophylactic antibiotic therapy is advocated. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 18, 2018 Category: Neurology Source Type: research

Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study
CONCLUSIONS In our study, the absence of a practice effect in Gd positive compared to Gd negative patients and to healthy controls suggests a possible role of focal inflammation on cognitive function of MS patients. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 16, 2018 Category: Neurology Source Type: research

Expiratory and phonation times as measures of disease severity in patients with Multiple Sclerosis. A case-control study
Conclusions As the expiratory times were significantly correlated with the EDSS scores, they could be used to measure the severity of MS and to monitor its progression. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Dimethyl fumarate downregulates the immune response through the HCA2/GPR109A pathway: implications for the treatment of multiple sclerosis
Conclusion Although the DMF/MMF mechanism of action remains unclear, evidence suggests that the activation of HCA2/GPR109A pathway downregulates the immune response and may activate anti-inflammatory response in the intestinal mucosa, possibly leading to reduction in CNS tissue damage in MS patients. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Cauda equina involvement following dengue fever
Publication date: Available online 30 April 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Beuy Joob, Viroj Wiwanitkit (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Impulsivity traits in patients with multiple sclerosis
Conclusion Patients with MS showed higher levels of cognitive impulsivity than subjects without MS. Objective measures for impulsiveness further support this finding. Impulsiveness scales scores might be biased by depression, which should be considered when assessing impulsivity in MS. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Forkhead box C1 gene variant causing glaucoma and small vessel angiopathy can mimic multiple sclerosis
Publication date: May 2018 Source:Multiple Sclerosis and Related Disorders, Volume 22 Author(s): Jagannadha R. Avasarala, Julie R. Jones, Curtis R. Rogers A 34–year old Caucasian female was initially diagnosed with multiple small-vessel strokes at age 20 years which were etiologically classified as secondary to anti-phospholipid antibody syndrome (APS) although she had no history or laboratory data to suggest APS. Based on her MRI of brain findings, one of her neurologists was concerned she could have multiple sclerosis (MS) and hence the patient was referred to our clinic for further evaluation. The patient's MRI o...
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
Conclusions In TOP patients with a median (range) baseline EDSS score of 3.5 (0.0–9.5) who completed 24 months of natalizumab treatment, the rate of 48-week confirmed disability worsening events was below 15%; after approximately 5.5 years of natalizumab treatment, 86.5% and 94.7% of patients did not have EDSS score increases of ≥1.0 or ≥2.0 points, respectively. The presence of relapses was associated with higher rates of overall disability worsening. These results were confirmed by assessing transition to EDSS milestones. Lower rates of overall 48-week confirmed EDSS worsening and of transitioning from EDSS s...
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Yawning and cortisol levels in multiple sclerosis: potential new diagnostic tool
Publication date: Available online 2 May 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Simon B N Thompson, Alister Coleman, Nicola Williams Yawning is a significant behavioural response and, together with cortisol, is potentially a new diagnostic marker of neurological diseases. Evidence of an association between yawning and cortisol was found which supports the Thompson Cortisol Hypothesis and thermoregulation hypotheses, indication that brain cooling occurs when yawning. 117 volunteers aged 18-69 years were randomly allocated to experimentally controlled conditions to provoke yawning. Thirty-three had ...
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Timed instrumental activities of daily living in multiple sclerosis: The test of everyday cognitive ability (TECA)
Conclusions : The TECA is a TIADLs assessment appropriate for use in those with MS as it includes a broad range of task difficulties, requires minimum motor involvement, and is sensitive to MS-related cognitive impairment. The TECA is a brief and repeatable test of TIADLs and its ease of administration makes it suitable for both clinical practice and research settings. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Small-scale geographical variation in multiple sclerosis: a case-control study using Danish register data 1971-2013
Conclusions Small-scale geographical variation in the risk of MS suggests that local environmental risk factors could be at play and may be related to life style factors. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Effect of Intermittent vs. Daily Calorie Restriction on Changes in Weight and Patient-Reported Outcomes in People with Multiple Sclerosis
Publication date: Available online 5 May 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Kathryn C. Fitzgerald, Diane Vizthum, Bobbie Henry-Barron, Amy Schweitzer, Sandra D. Cassard, Eric Kossoff, Adam L. Hartman, Dimitrios Kapogiannis, Patrick Sullivan, David J. Baer, Mark P. Mattson, Lawrence J. Appel, Ellen M. Mowry An intermittent fasting or calorie restriction diet has favorable effects in the mouse forms of multiple sclerosis (MS) and may provide additional anti-inflammatory and neuroprotective advantages beyond benefits obtained from weight loss alone. We conducted a pilot randomized controlled feed...
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder
Conclusion The evidence suggests that there may be a risk of vaccination-associated relapses among untreated neuromyelitis optica spectrum disorder patients, however immunosuppressive therapy at time of vaccine may abort the risk; this suggests that the patients who are treated with preventive immune suppression and receive routine vaccinations for common infections may fare better. Further prospective studies are necessary to verify these findings. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Reliability and Validity of the DYMUS Questionnaire for the assessment of dysphagia in Multiple Sclerosis (Greek version) and proposed modification
Conclusions The Greek version of DYMUS was found to be a valid, reliable and practical for clinical use questionnaire for the detection of dysphagia in Multiple Sclerosis. The first reported normative data for DYMUS suggest a cut-off for the diagnosis of dysphagia at 2 and our findings support a modification of DYMUS eliminating the question about weight loss. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

The efficacy of vitamin D in multiple sclerosis: a meta-analysis
Conclusion Our findings suggest that vitamin D appeared to have no therapeutic effect on EDSS score or ARR in the patients with MS. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod
We describe the case of a 50-year old man on fingolimod since 2011 who presented, in April 2017, with a voluminous swelling of the left tonsil. A left tonsillectomy was performed, and histological exam disclosed a papillary squamous cell carcinoma of the palatine tonsil, with an in situ hybridization positive for human papillomavirus (HPV)-16 DNA. Neither lymph nodes involvement nor other metastases were detected. Fingolimod was stopped as a precautionary measure in May 2017, and the patient currently continues his follow up at our Department. Immunocompromised patients are at risk for developing HPV-related malignancies p...
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion
Publication date: July 2018 Source:Multiple Sclerosis and Related Disorders, Volume 23 Author(s): Konstantina G Yiannopoulou, Dimitra Papadimitriou, Aikaterini I Anastasiou, Marina Siakantaris A 47-year-old Caucasian female with relapsing- remitting Multiple Sclerosis, received alemtuzumab after a serious relapse. She had ceased receiving any treatment during the previous year. 23 days after alemtuzumab infusion she developed severe early neutropenia, which resulted in septic shock by Staphylococcus aureus and death. This is the first report of alemtuzumab infusion-related death due to early neutropenia in non-immunocompr...
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Phase sensitive reconstruction of T1-weighted inversion recovery in the evaluation of the cervical cord lesions in multiple Sclerosis; is it similarly eligible in 1.5  T magnet fields?
Conclusion This study shows that in the setting of a 1.5 T magnet field, STIR significantly has a superiority over both of the PSIR reconstructions (i.e. real and magnitude) for the detection as well as the boundary definition of the cervical cord lesions of MS. These results have a good relevance to clinical practice by using MRI scanners and sequences routinely available, however, it is discrepant with other reports performed by 3 T Magnet fields. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Severe aseptic temporal lobe encephalitis on fingolimod
We report the case of an MS patient with aseptic temporal lobe encephalitis while on treatment with fingolimod. This 49-year-old woman developed headache and decreasing level of consciousness after 3.5 years of fingolimod therapy. Imaging, CSF studies, and rapid clinical response to acyclovir suggested a viral etiology, although CSF cultures and viral PCR were negative. This case illustrates the potential for severe manifestations of infectious illnesses on fingolimod, which may have a predilection for the CNS and also include herpes virus infections, cryptococcus, and PML. Efforts to prevent these secondary infections are...
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Trident sign trumps Aquaporin-4-IgG ELISA in diagnostic value in a case of longitudinally extensive transverse myelitis
We report a case in which the patient was initially diagnosed with neuromyelitis optical spectrum disorder, but where the “trident” sign ultimately led to the correct diagnosis of spinal cord sarcoidosis. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Autonomic dysreflexia following acute myelitis due to neuromyelitis optica
Conclusions This case report illustrates a clinically relevant, but still under-recognized cardiovascular autonomic complication of severe, cervical or high-thoracic spinal cord impairment due to NMO. In addition to low baseline blood pressure and orthostatic hypotension, the patient developed episodes of autonomic dysreflexia during the acute stage after tetraplegia. Autonomic dysreflexia requires early diagnosis and proper treatment in order to prevent severe complications or death. Greater awareness of this potentially life-threatening cardiovascular emergency of spinal cord impairment is needed among patients, caregive...
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Peripheral blood memory B cell frequency predicts conversion from clinically isolated syndrome to multiple sclerosis
Conclusion Our results suggest that conversion from CIS to MS occurs due to the inability of the immune system to suppress effector B cell production. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 15, 2018 Category: Neurology Source Type: research

Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: the first report from Iran
Conclusion These findings indicate NMOSD patients have lower HRQOL in compare to patients with MS. Also, screening and treatment of fatigue as the most important predictor for HRQOL is necessary. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - April 15, 2018 Category: Neurology Source Type: research

Frequent retinal ganglion cell damage after acute optic neuritis
Conclusion Inter-ocular GCIP identifies significantly more eyes suffering damage from ON than absolute GCIP, visual fields or visual acuity loss. Effective interventional options are needed to prevent ganglion cell loss. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - April 10, 2018 Category: Neurology Source Type: research

Dysregulation of NRXN1 by mutant MIR8485 leads to calcium overload in pre-synapses inducing neurodegeneration in Multiple Sclerosis
Conclusions Mutations in miR-8485 and NRXN1 was found to alter calcium homeostasis and NRXN1/NLGN1 cell adhesion molecule binding affinities. The miR-8485 mutation leads to overexpression of NRXN1 altering pre-synaptic Ca2+ homeostasis, inducing neurodegeneration. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - April 10, 2018 Category: Neurology Source Type: research

Recommended outcome measures for inpatient rehabilitation of multiple sclerosis are not appropriate for the patients with substantially impaired mobility
Conclusions Currently used outcome measures are inadequate for patients with impaired mobility, and there is a dire need of specifically designed outcome measures for routine care that are less burdensome and short-term responsive. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - April 5, 2018 Category: Neurology Source Type: research

Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis – a non-infectious cause of breathlessness
We describe a case of a sub-acute steroid responsive non-infectious pneumonitis affecting a 51 year old woman, who presented one month after initiation of therapy for multiple sclerosis with alemtuzumab. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - April 4, 2018 Category: Neurology Source Type: research

Spanish validation of a specific measure to assess work-related problems in people with multiple sclerosis: the Multiple Sclerosis Work Difficulties Questionnaire (MSWDQ-23)
Conclusion The Spanish version of the MSWDQ-23 shows appropriate feasibility, reliability, and discriminative performance as a patient-reported outcome. MSWDQ-23 may be a valuable addition to measure the impact of a comprehensive spectrum of difficulties experienced by people with MS in the workplace. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - April 4, 2018 Category: Neurology Source Type: research

Lifestyle factors and multiple sclerosis: A population-based incident case-control study
Conclusion In a middle-eastern setting, we found that sun exposure during adolescence, drug abuse, and alcohol use were all associated with MS. Increasing sun exposure and reducing drug abuse and the use of alcohol through educational programs is likely to reduce the rate of MS. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - April 1, 2018 Category: Neurology Source Type: research

Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab
Publication date: Available online 29 March 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Martin W. Hümmert, Julian Deppe, Refik Pul, Ulrich Wurster, Philipp Schwenkenbecher, Kurt-Wolfram Sühs, Paul Bronzlik, Martin Stangel, Thomas Skripuletz Natalizumab is highly effective in the treatment of relapsing multiple sclerosis patients. Unfortunately, after stopping natalizumab, there is an increased risk of inflammation in the central nervous system and relapses. Switching from natalizumab to an alternative sufficient drug may prevent disease reactivation. Here we present a case of a patient who ex...
Source: Multiple Sclerosis and Related Disorders - March 30, 2018 Category: Neurology Source Type: research

Improving fatigue in Multiple Sclerosis by smartphone-supported energy management: the MS TeleCoach feasibility study
Conclusion Using MS TeleCoach as a self-management tool in pwMS suffering from mild disability and moderate to severe fatigue appeared to be feasible, both technically and from a content perspective. Its use was associated with improved fatigue levels in the participants who completed the study. The MS Telecoach seems to meet the need for a low-cost, accessible and interactive self-management tool in MS. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 28, 2018 Category: Neurology Source Type: research

Characterisation of cardiac autonomic function in multiple sclerosis based on spontaneous changes of heart rate and blood pressure
Conclusions The results, using techniques novel to MS investigation, showed diminished baroreceptor reflex and impaired sympathetic function using frequency domain systolic blood pressure variability analysis. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 28, 2018 Category: Neurology Source Type: research

Early Infectious Exposures are Not Associated with Increased Risk of Pediatric-Onset Multiple Sclerosis
Conclusion Early infectious factors investigated in this study were not associated with MS risk. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 27, 2018 Category: Neurology Source Type: research

B cell depleting therapy for multiple sclerosis overlapping with neuromyelitis optica spectrum disorder
We describe a patient with frequently relapsing demyelinating episodes and repeatedly adjusted treatment regimens due to diagnostic difficulties. This case did not respond adequately to glucocorticoid plus azathioprine or to interferon. Benefits were finally obtained by using rituximab, an anti-CD20 specific monoclonal antibody targeting B cells. Treatments targeting B cell mediated humoral immunity such as rituximab, may be a safe and appropriate choice for these challenging demyelinating cases, especially in Asian population. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 27, 2018 Category: Neurology Source Type: research

Response to Letter to the Editors
Publication date: Available online 26 March 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Gary Birnbaum, Jessica Stulc (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 27, 2018 Category: Neurology Source Type: research

Prevalence of and Risk Factors for Cognitive Impairment in Patients with Relapsing-Remitting Multiple Sclerosis: Multi-center, Controlled Trial
Conclusions This is the first national cognitive data obtained from MS in Turkey, which is a country between Europe and Asia and thus has characteristics of both continents. The similarity of the results of the present study obtained from Turkey to the Western-based data indicates that CI is universal in MS and the main factors affecting CI have not changed. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 24, 2018 Category: Neurology Source Type: research

Reply to tsivgoulis and colleagues comments
Publication date: Available online 24 March 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Douglas S. Goodin, Dimos D. Mitsikostas (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 24, 2018 Category: Neurology Source Type: research

Letter to the editor to the paper: “Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis”
Publication date: May 2018 Source:Multiple Sclerosis and Related Disorders, Volume 22 Author(s): Tjalf Ziemssen, Volker Limmroth (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 23, 2018 Category: Neurology Source Type: research

Comment on Y.D. Fragoso et al.: “Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod” Multiple Sclerosis and Related Disorders 2017
Publication date: Available online 22 March 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Katja Akgün, Maxi Kaufmann, Tjalf Ziemssen (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 22, 2018 Category: Neurology Source Type: research

Are the high-costs of MS disease-modifying therapies justified?
Publication date: February 2018 Source:Multiple Sclerosis and Related Disorders, Volume 20 Author(s): Gavin Giovannoni, Chris Hawkes, Michael Levy, Emmanuelle Waubant (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 21, 2018 Category: Neurology Source Type: research

Evolution of multiple sclerosis prevalence and phenotype in Latin America
Conclusion MS epidemiology in Latin American patients has distinctive features. Both, prevalence and incidence, are increasing. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 21, 2018 Category: Neurology Source Type: research

Letter to the editor to the paper: „ “Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis“
Publication date: Available online 19 March 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Tjalf Ziemssen, Volker Limmroth (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 19, 2018 Category: Neurology Source Type: research

Optical coherence tomography as a biomarker of neurodegeneration in multiple sclerosis: A review
Publication date: Available online 16 March 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Ricardo Alonso, Dolores Gonzalez-Moron, Orlando Garcea Neurodegeneration is one the most important pathological factors which contributes to permanent disability in multiple sclerosis (MS). Optical coherence tomography (OCT) measurements of macular ganglion cell layer (mGCL) and retinal nerve fiber layer (RNFL) have been proposed as biomarkers of axonal damage in MS. The aim of this review is to describe the most relevant findings regarding OCT and axonal damage in MS. We have selected studies that describe retina i...
Source: Multiple Sclerosis and Related Disorders - March 17, 2018 Category: Neurology Source Type: research

Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis
Publication date: Available online 15 March 2018 Source:Multiple Sclerosis and Related Disorders Author(s): Georgios Tsivgoulis, Aristeidis H. Katsanos, Konstantinos Voumvourakis, Georgios M. Hadjigeorgiou, Ioannis Heliopoulos, Theodore Karapanayiotides, Panagiotis Papathanasopoulos, Constantinos Kilidireas, Nikolaos Grigoriadis (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 16, 2018 Category: Neurology Source Type: research

Preliminary investigation of cognitive function in aged multiple sclerosis patients: Challenges in detecting comorbid Alzheimer ’s disease
Conclusion Our findings suggest that the cognitive profiles of MS and AD are distinct. In contrast to AD, MS is not associated with impairment of memory consolidation. However, there may be overlap between cognitive deficits related to MS and aMCI. Thus, evidence of poor memory retention, in an older MS patient may merit comprehensive dementia evaluation. The study is preliminary and includes no AD biomarkers (e.g., amyloid imaging) to confirm or rule out AD pathology. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 14, 2018 Category: Neurology Source Type: research

Physiotherapeutic interventions in multiple sclerosis across Europe: regions and other factors that matter
Conclusions To our knowledge this is the first study that has explored this topic in MS. The results broaden our understanding of the different PT interventions used in MS, as well as the context of their use. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 14, 2018 Category: Neurology Source Type: research

Online validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis
Publication date: April 2018 Source:Multiple Sclerosis and Related Disorders, Volume 21 Author(s): L. Lavorgna, G. Miele, M. Petruzzo, R. Lanzillo, S. Bonavita (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - March 14, 2018 Category: Neurology Source Type: research